A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-11

Study Completion Date

2023-07-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary goal for this study is to evaluate the safety and reactogenicity of 3 dose levels of mRNA-1283 and 1 dose level of mRNA-1273 vaccine given to healthy adults in 2 doses, 28 days apart, and 1 dose level of mRNA-1283 administered as a single dose to healthy adults.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

NCT07266558

SARS-CoV-2

RECRUITING PHASE4

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427

SARS-CoV-2

COMPLETED PHASE3

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

NCT04283461

COVID-19 COVID-19 Immunisation

COMPLETED PHASE1

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

NCT04649151

SARS-CoV-2

COMPLETED PHASE2/PHASE3

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

NCT03392389

Human Metapneumovirus and Human Parainfluenza Infection

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV-2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Participants who are offered an opportunity to receive an additional injection of mRNA-1273, will participate in an open-label part of the study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

mRNA-1283 Dose Level 1

Participants will receive 2 intramuscular (IM) injections of mRNA-1283 at Dose Level 1 on Day 1 and Day 29.

Group Type EXPERIMENTAL

mRNA-1283

Intervention Type BIOLOGICAL

Sterile liquid for injection

mRNA-1283 Dose Level 2

Participants will receive 2 IM injections of mRNA-1283 at Dose Level 2 on Day 1 and Day 29.

Group Type EXPERIMENTAL

mRNA-1283

Intervention Type BIOLOGICAL

Sterile liquid for injection

mRNA-1283 Dose Level 3

Participants will receive 2 IM injections of mRNA-1283 at Dose Level 3 on Day 1 and Day 29.

Group Type EXPERIMENTAL

mRNA-1283

Intervention Type BIOLOGICAL

Sterile liquid for injection

mRNA-1273

Participants will receive 2 IM injections of mRNA-1273 at a pre-specified dose for this study on Day 1 and Day 29.

Group Type EXPERIMENTAL

mRNA-1273

Intervention Type BIOLOGICAL

Sterile liquid for injection

Placebo / mRNA-1283

Participants will receive 1 IM injection of study drug-matching placebo on Day 1 and 1 IM injection of mRNA-1283 at a pre-specified dose on Day 29. Participants may be offered an opportunity to receive an additional injection of mRNA-1273 at the pre-specified dose on Open-Label Day 1.

Group Type EXPERIMENTAL

mRNA-1283

Intervention Type BIOLOGICAL

Sterile liquid for injection

Placebo

Intervention Type BIOLOGICAL

0.9% sodium chloride (normal saline) injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mRNA-1283

Sterile liquid for injection

Intervention Type BIOLOGICAL

mRNA-1273

Sterile liquid for injection

Intervention Type BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) injection

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Understands and agrees to comply with the study procedures and provides written informed consent.
* According to the assessment of the investigator, is in good general health and can comply with study procedures.
* Body mass index (BMI) of 18 kilograms/square meter (kg/m\^2) to 35 kg/m\^2 (inclusive) at the Screening Visit (Day 0).
* For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection, agreement to continue adequate contraception or abstinence through 3 months following the second injection, and not currently breastfeeding.

Exclusion Criteria

* Known history of SARS-CoV-2 infection or known exposure to someone with SARS-CoV-2 infection or COVID-19 in the past 30 days.
* Positive serology results for SARS-CoV-2 at the Screening Visit. A negative serological test for SARS-CoV-2, performed on a blood sample obtained at the Screening Visit, is required before a participant can be dosed.
* Travel outside of the United States in the 28 days prior to the Screening Visit (Day 0).
* Prior administration of an investigational, authorized, or licensed CoV (for example, SARS-CoV-2, SARS-CoV, or Middle East Respiratory Syndrome \[MERS\]-CoV) vaccine, based on medical history interview.
* Current treatment with investigational agents for prophylaxis against COVID-19.
* Recent (within the last 12 months) use of a dermal filler.
* Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
* Has received systemic immunosuppressants or immune-modifying drugs for \>14 days in total within 6 months prior to Screening (for corticosteroids, 10 milligrams (mg)/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
* Has received or plans to receive any licensed vaccine 28 days prior to the first injection (Day 1) or plans to receive a licensed vaccine within 28 days before or after any study injection, with the exception of licensed influenza vaccines, which may be received more than 14 days before the first study injection or more than 14 days after the second study injection.
* Receipt of systemic immunoglobulins or blood products within 3 months prior to the Screening Visit (Day 0) or plans for receipt during the study.
* Current use of any inhaled substance (for example, tobacco or cannabis smoke, nicotine vapors).
* History of chronic smoking (1 cigarette a day) within 1 year of the Screening Visit.
* Resides in a nursing home.
* Has donated 450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the study.
* Participated in an interventional clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to do so while participating in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes